title: Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.
abstract: Glucocorticoids act directly on bone cells to decrease production of osteoblasts and osteoclasts, increase osteoblast and osteocyte apoptosis, and prolong osteoclast life span. Conversely, daily injections of PTH decrease osteoblast and osteocyte apoptosis and increase bone formation and strength. Using a mouse model, we investigated whether the recently demonstrated efficacy of PTH in glucocorticoid-induced bone disease results from the ability of this therapeutic modality to counteract at least some of the direct effects of glucocorticoids on bone cells. Glucocorticoid administration to 5- to 6-month-old Swiss-Webster mice for 28 d increased the prevalence of osteoblast and osteocyte apoptosis and decreased osteoblast number, activation frequency, and bone formation rate, resulting in reduced osteoid, wall and trabecular width, bone mineral density, and bone strength. In contrast, daily injections of PTH caused a decrease in osteoblast and osteocyte apoptosis and an increase in osteoblast number, activation frequency, bone formation rate, bone mineral density, and bone strength. The decreased osteocyte apoptosis was associated with increased bone strength. When the two agents were combined, all the adverse effects of glucocorticoid excess on bone were prevented. Likewise, in cultured osteoblastic cells, PTH attenuated the adverse effects of glucocorticoids on osteoblast survival and Wnt signaling via an Akt phosphorylation-dependent mechanism. We conclude that intermittent PTH administration directly counteracts the key pathogenetic mechanisms of glucocorticoid excess on bone, thus providing a mechanistic explanation of its efficacy against glucocorticoid-induced osteoporosis.
authors.affiliation: University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 587, Little Rock, Arkansas 72205-7199, USA. weinsteinroberts@uams.edu
authors.forename: Robert S
authors.initials: RS
authors.lastname: Weinstein
authors.forename: Robert L
authors.initials: RL
authors.lastname: Jilka
authors.forename: Maria
authors.initials: M
authors.lastname: Almeida
authors.forename: Paula K
authors.initials: PK
authors.lastname: Roberson
authors.forename: Stavros C
authors.initials: SC
authors.lastname: Manolagas
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D002460:Cell Line; D005938:Glucocorticoids / Q000494:pharmacology*; D051379:Mice; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects*; D010011:Osteocytes / Q000166:cytology / Q000187:drug effects*; D010012:Osteogenesis / Q000187:drug effects; D010281:Parathyroid Hormone / Q000494:pharmacology*; D011239:Prednisolone / Q000494:pharmacology
chemical_list: D005938:Glucocorticoids; D010281:Parathyroid Hormone; D011239:Prednisolone
references.citation: Aging Cell. 2010 Apr;9(2):147-61
references.pmid: 20047574
references.citation: Rev Endocr Metab Disord. 2001 Jan;2(1):65-73
references.pmid: 11708295
references.citation: J Clin Invest. 1999 Nov;104(10):1363-74
references.pmid: 10562298
references.citation: N Engl J Med. 2007 Nov 15;357(20):2028-39
references.pmid: 18003959
references.citation: Calcif Tissue Int. 1998 Jun;62(6):475-80
references.pmid: 9576972
references.citation: Biochem Biophys Res Commun. 2009 Feb 6;379(2):261-6
references.pmid: 19101512
references.citation: J Biol Chem. 2005 Dec 16;280(50):41342-51
references.pmid: 16251184
references.citation: J Bone Miner Res. 1989 Apr;4(2):137-41
references.pmid: 2658477
references.citation: Cell. 1995 Jun 2;81(5):727-36
references.pmid: 7774014
references.citation: Bone. 2010 Mar;46(3):564-70
references.pmid: 19591965
references.citation: J Biol Chem. 2005 Jan 21;280(3):2388-94
references.pmid: 15537647
references.citation: J Bone Miner Res. 2010 Feb;25(2):178-89
references.pmid: 19594304
references.citation: Science. 1998 Sep 4;281(5382):1509-12
references.pmid: 9727977
references.citation: Bone. 1995 Jun;16(6):603-10
references.pmid: 7669436
references.citation: J Bone Miner Res. 2007 Oct;22(10):1492-501
references.pmid: 17542686
references.citation: Endocrinology. 2003 May;144(5):2008-15
references.pmid: 12697709
references.citation: J Bone Miner Res. 2007 Jan;22(1):55-63
references.pmid: 17014384
references.citation: Arthritis Rheum. 2009 Nov;60(11):3346-55
references.pmid: 19877063
references.citation: Arthritis Rheum. 2008 Nov;58(11):3485-97
references.pmid: 18975341
references.citation: Genes Dev. 2008 Nov 1;22(21):2968-79
references.pmid: 18981475
references.citation: Endocr Rev. 2005 Aug;26(5):688-703
references.pmid: 15769903
references.citation: J Biol Chem. 2007 Sep 14;282(37):27285-27297
references.pmid: 17623659
references.citation: Trends Endocrinol Metab. 2010 Apr;21(4):237-44
references.pmid: 20074973
references.citation: Lancet. 1998 Oct 24;352(9137):1327-8
references.pmid: 9802265
references.citation: J Bone Miner Res. 1987 Dec;2(6):595-610
references.pmid: 3455637
references.citation: Endocrinology. 2005 Nov;146(11):4577-83
references.pmid: 16081646
references.citation: Endocrinology. 2004 Apr;145(4):1980-7
references.pmid: 14715712
references.citation: J Biol Chem. 2002 Dec 13;277(50):48868-75
references.pmid: 12364326
references.citation: J Clin Invest. 1998 Oct 15;102(8):1627-33
references.pmid: 9788977
references.citation: Endocrinology. 2004 Apr;145(4):1835-41
references.pmid: 14691012
references.citation: Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2259-64
references.pmid: 17287359
references.citation: Bone. 2007 Feb;40(2):354-9
references.pmid: 17046344
references.citation: J Clin Invest. 1998 Jul 15;102(2):274-82
references.pmid: 9664068
references.citation: Life Sci. 2009 Nov 4;85(19-20):685-92
references.pmid: 19782693
references.citation: J Musculoskelet Neuronal Interact. 2000 Sep;1(1):53-6
references.pmid: 15758526
references.citation: J Cell Biochem. 1999 Sep 1;74(3):357-71
references.pmid: 10412038
references.citation: Bone. 2006 Aug;39(2):244-52
references.pmid: 16503210
references.citation: J Clin Invest. 1999 Aug;104(4):439-46
references.pmid: 10449436
references.citation: Cancer Res. 1983 Sep;43(9):4308-14
references.pmid: 6575864
references.citation: Calcif Tissue Int. 1983 Jul;35(4-5):410-7
references.pmid: 6616314
references.citation: Lancet. 1998 Dec 12;352(9144):1940
references.pmid: 9863825
references.citation: J Clin Invest. 2002 Apr;109(8):1041-8
references.pmid: 11956241
references.citation: J Clin Endocrinol Metab. 2002 Sep;87(9):4033-41
references.pmid: 12213840
references.citation: Bone. 2007 Jun;40(6):1434-46
references.pmid: 17517365
references.citation: Lancet. 1976 May 15;1(7968):1035-8
references.pmid: 57447